Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network.
David García-VegaDavid Sánchez-LópezGemma Rodríguez-CarneroRocío Villar-TaiboJuan E ViñuelaAdán Lestegás-SotoAna Seoane-BlancoMaría Moure-GonzálezSusana B BravoÁngel L FernándezJosé R González-JuanateySonia EirasPublished in: Cardiovascular diabetology (2024)
Semaglutide increases endocrine activity of epicardial fat with antithrombotic properties. Moreover, this drug modulates the pro-inflammatory and atherogenic profile induced by the adiposity marker, FABP4, which is also reduced in patients after semaglutide treatment.
Keyphrases
- endothelial cells
- end stage renal disease
- adipose tissue
- ejection fraction
- chronic kidney disease
- newly diagnosed
- fatty acid
- prognostic factors
- peritoneal dialysis
- insulin resistance
- atrial fibrillation
- type diabetes
- emergency department
- metabolic syndrome
- binding protein
- patient reported outcomes
- skeletal muscle
- body mass index
- drug induced